Ukubuyekezwa okuhlelekile kanye nami kukaSakuraba neminye imibiko evela eNyuvesi yaseChicagoImiphumela yokuhlaziya ikhombisa ukuthi iziguli ezinesifo esingalapheki sesibindi zisengozini enkulu yomdlavuza obala ngokobulili (CRC), noma ngabe lezi ziguli zithola ukufakelwa isibindi, le ngozi isekhona. (Gastrointestinal Endosc. Uhlobo oluku-inthanethi ngoDisemba 21, 2016)
USakuraba uthe noma ngabe yini imbangela yesifo sesibindi, iziguli ezinesifo esingalapheki sesibindi zisengozini enkulu ye-CRC, futhi le ngozi isekhona ngemuva kokufakwa kwesibindi. Ngakho-ke, iziguli ezinesifo esingalapheki sesibindi kufanele zihlolwe noma zibhekwe ngamandla amakhulu ukunciphisa ubungozi beCRC.
USakuraba et al. Kuhlolwe ubungozi be-CRC ezigulini ezinesifo esingalapheki sesibindi ngaphambi nangemva kokufakelwa kwesibindi. Abaphenyi bacwaninga izifundo zobungozi besifo esingalapheki sesibindi kanye neCRC ngokusebenzisa i-database kagesi futhi bahlola iziguli ezingama-55 991 ezifundweni ezingama-50. According to Sakuraba, in studies that included patients with hepatitis and cirrhosis, the total standardized incidence rate (SIR) was 2.06 (95% CI 1.46 ~ 2.90, P <0.0001), and the heterogeneity was moderate (I2 = 49.2%) This is most likely due to differences in disease subgroups and research intensity.
Izifundo ezintathu zikhombisile ukuthi iziguli ezine-primary sclerosing cholangitis (PSC) zinengozi eyengeziwe ye-CRC (SIR = 6.70, 95% CI 3.48-12.91; P <0.0001), kanye ne-heterogeneity elinganiselayo (I2 = 36.3%), Ngokusobala lokhu kufanele ekwehlukeni kokuqina kocwaningo. Kulezo zifundo ezazibandakanya iziguli ezazifakelwa isibindi, i-SIR yayingu-2.16 (95% CI 1.59 kuya ku-2.94, P <0.0001), kanti i-heterogeneity yayilingana (I2 = 56.4%).
Mina Ekuhlaziyeni kwe-ta, ingxenye yezifo zesibindi ezihlobene ne-autoimmune yayihlobene nengozi ye-CRC. USakuraba uthe, "Phambilini bekucatshangwa ukuthi iziguli ze-PSC kuphela ezizoba sengozini eyengeziwe ye-CRC, kodwa ucwaningo lwethu lubonise ukuthi ingozi ye-CRC phakathi kweziguli ezinezinye izifo zesibindi ezingamahlalakhona nayo izokhuphuka. Ukwanda okufanayo kubaluleke kakhulu. “
Patrick Boland from the Roswell Park Cancer Institute in New York is not a member of the study. He pointed out that most of the patients in the study have cirrhosis, PSC or have received liver transplantation. The risk of CRC in PSC patients is particularly obvious. PSC is associated with inflammatory bowel disease, which is a known risk factor for umdlavuza colon, which is also the strongest evidence. However, those who have undergone liver transplantation, especially those with underlying autoimmune diseases, have an increased risk of CRC. Organ transplantation requires the use of immunosuppressive agents, which puts the patient at risk of secondary malignancy for a long time. They have evidence that kidney transplant patients have an increased risk of colon cancer. The data from this study showed that the risk of colon cancer in patients who underwent liver transplantation would be doubled.
UBoland uthe lokhu okutholakele akukusha, ngoba ukuvuvukala kanye nokucindezelwa komzimba yizinto ezinobungozi zomdlavuza wekoloni. Ukholelwa ukuthi i-colonoscopy ingaba yingxenye yokuhlolwa kokuhlinzwa kwesibindi se-metastases, ikakhulukazi ezigulini ezine-PSC. Ubalule nokuthi ngenxa yokuthi izimila ezenzeka ezingxenyeni ezehlukene zamathumbu amakhulu zinokwehluka okukhulu kwemvelo, kuzothokozisa ukuqhubeka nokufunda ukuthi ngabe ubungozi besifo buhlobene ikakhulu nekholoni lesobunxele noma lesokudla.
